DarioHealth Corp. — fact timeline

Steven Nelson changed role as President and Chief Commercial Officer at DarioHealth Corp..

“On July 10, 2026, the temporary medical leave of absence of Steven Nelson, President and Chief Commercial Officer of DarioHealth Corp., or the Company, was extended for an indefinite period.”

DarioHealth Corp. entered into Sales Agreement with A.G.P./Alliance Global Partners valued at $20,000,000 (effective 2026-03-30).

“On March 30, 2026, DarioHealth Corp., a Delaware corporation (the “Company”), entered into a sales agreement (the “Sales Agreement”) with A.G.P./Alliance Global Partners (the “Agent”), pursuant to which the Company may issue and sell, from time to time, up to an aggregate of $20,000,000 of shares of its common stock”

DarioHealth Corp.: Amended and Restated Certificate of Incorporation to expressly authorize the Board of Directors to alter and repeal the company's bylaws, subject to stockholder power (effective 2026-02-02).

“On February 2, 2026, DarioHealth Corp. (the “Company”) filed an Amended and Restated Certificate of Incorporation (“Amended Charter”) with the Secretary of State of the State of Delaware amending the Company’s Certificate of Incorporation to expressly authorize the Company’s Board of Directors to alter and repeal the Company’s bylaws, subject to the power of the Company’s stockholders to alter or repeal the bylaws.”

DarioHealth Corp. issued 2,713,180 shares of common stock of common stock to purchasers in a private placement for $6.45 per share.

“health market, today announced a private placement for the purchase and sale of 2,713,180 shares of common stock (or common stock equivalents in lieu thereof) at a price of $6.45 per share for expected aggregate gross proceeds of approximately $ 17.5 million, before deducting offering expenses. The closing of the offering is expected to occur on or about”

DarioHealth Corp.: Amended Series C-1 Certificate of Designation to accelerate mandatory conversion period (effective 2025-09-25).

“On September 25, 2025, the Company, upon obtaining the vote of a majority of the holders of the relevant classes of preferred stock and the approval of the Company’s Board of Directors, filed an Amended and Restated Certificate of Designation of Preferences, Rights and Limitations of the Company’s Series C-1 Preferred Stock (the “Series C-1 Certificate of Designation”) with the Secretary of State of the State of Delaware. The Series C-1 Certificate of Designation was amended to accelerate the mandatory conversion period of all outstanding shares of such series into shares of the Company’s common stock, or at each holder’s election in pre-funded warrants, effective as of September 25, 2025.”

DarioHealth Corp.: Amended and restated certificates of designation for Series A-1, Series C, C-2, D, D-1, D-2, and D-3 preferred stock to accelerate mandatory conversion period and provide option for pre-funded warrants (effective 2025-09-18).

“On September 18, 2025, DarioHealth Corp. (the “Company”), upon obtaining the vote of a majority of the holders of the relevant classes of preferred stock and the approval of the Company’s Board of Directors, filed an Amended and Restated Certificate of Designation of Preferences, Rights and Limitations of the Company’s Series A-1 Preferred Stock (the “Series A-1 Certificate of Designation”), an Amended and Restated Certificate of Designation of Preferences, Rights and Limitations of the Company’s Series C Preferred Stock (the “Series C Certificate of Designation”), an Amended and Restated Certificate of Designation of Preferences, Rights and Limitations of the Company’s Series C-2 Preferred Stock (the “Series C-2 Certificate of Designation”, collectively with the Series C Certificate of Designation, the “Series C Certificates of Designation”), an Amended and Restated Certificate of Designation of Preferences, Rights and Limitations of the Company’s Series D Preferred Stock (the “Series”

DarioHealth Corp.: The company amended its certificate of incorporation to effect a 20-for-1 reverse stock split, effective August 28, 2025 (effective 2025-08-28).

“Effective as of August 28, 2025, DarioHealth Corp. (the “Company”) will effect a reverse stock split of its outstanding shares of common stock at a ratio of twenty -for- one (the “Reverse Split”).”

DarioHealth Corp.: Amended Series A-1 and Series B-1 Certificates of Designation to allow dividends/distributions in the form of pre-funded common stock purchase warrants instead of common stock (effective 2025-05-20).

“On May 20, 2025, the Company, upon obtaining the vote of a majority of the holders of the relevant classes of preferred stock, filed an Amended and Restated Certificate of Designation of Preferences, Rights and Limitations of the Company’s Series A-1 Preferred Stock (the “Series A-1 Certificate of Designation”) and a Third Amended and Restated Certificate of Designation of Preferences, Rights and Limitations of the Company’s Series B-1 Preferred Stock”

DarioHealth Corp.: Amended the Series C, C-1, and C-2 Certificates of Designation to extend the mandatory conversion period from 15 to 24 months and add a quarterly dividend of 15% of Common Stock issuable upon conversion (effective 2025-05-20).

“On May 20, 2025, DarioHealth Corp. (the “Company”), upon obtaining the vote of a majority of the holders of the relevant classes of preferred stock, filed an Amended and Restated Certificate of Designation of Preferences, Rights and Limitations of the Company’s Series C Preferred Stock”

DarioHealth Corp. incurred credit facility of $32.5 million with Callodine Commercial Finance, LLC at Term SOFR Rate plus 7.75% maturing April 2030.

“Under the terms of the Credit Agreement, each Lender agreed to make a multi-draw term loan to the Company (each a “Term Loan”) in which the Company borrowed $32.5 million at the time of closing on April 30, 2025.”

Chen Franco-Yehuda was appointed as Chief Financial Officer, Treasurer and Secretary at DarioHealth Corp..

“On April 18, 2025, the Board of Directors of the Company appointed Chen Franco-Yehuda, age 41, to serve as the Company’s Chief Financial Officer, Treasurer and Secretary, effective as of May 15, 2025.”

Zvi Ben-David resigned as Chief Financial Officer, Treasurer and Secretary at DarioHealth Corp..

“On April 18, 2025, Mr. Zvi Ben-David resigned as Chief Financial Officer, Treasurer and Secretary of DarioHealth Corp. (the “Company”), effective as of May 15, 2025.”

DarioHealth Corp. received a nasdaq extension granted notice regarding minimum bid price (rules 5550(a)(2), 5810(c)(3)(A)).

“March 18, 2025, the Company received a letter (the “Letter”), from the Staff approving an extension of an additional 180 calendar days from the date of the Letter, or until September 15, 2025 (the “Additional Compliance Period”) to regain compliance with the Minimum Bid Price Requirement. The Company’s Common Stock will continue to trade under the symbol “DRIO.” If at any time during the Additional Compliance Period, the bid price of the Common Stock closes at or above $1.00 per share for a minimum of ten (10) consecutive trading days, Nasdaq will provide the Company with written confirmation”

Jon Kaplan resigned as member of the Board at DarioHealth Corp..

“On February 24, 2025, Jon Kaplan voluntarily resigned from his position as a member of the Board.”

Lawrence Leisure was appointed as member of the Board at DarioHealth Corp..

“On February 25, 2025, on the recommendation of the Nominating Committee of the Board of Directors, or the Board, of DarioHealth Corp., or the Company, appointed Lawrence Leisure as a member of the Board, effective immediately.”

Richard Anderson departed as President at DarioHealth Corp..

“the Company and Richard Anderson, the Company’s President, mutually agreed for Mr. Anderson to cease serving in his role as President of the Company.”

Steven Nelson was appointed as Chief Commercial Officer at DarioHealth Corp..

“appointed Steven Nelson, age 51, to serve as its Chief Commercial Officer.”

DarioHealth Corp. completed an acquisition involving Twill, Inc..

“the Company’s acquisition of Twill, Inc., a Delaware corporation (“Twill”), pursuant to which the Company, through its subsidiary, TWILL Merger Sub, Inc., acquired all of the outstanding securities of Twill.”

DarioHealth Corp.: Reduced the stockholder meeting quorum requirement to 33 1/3% (effective 2024-04-16).

“The Bylaws were revised to reduce the quorum requirement at any meeting of the Company’s stockholders to thirty-three and one-third percent (33 1/3%) of the stock issued and outstanding and entitled to vote at such meeting.”

DarioHealth Corp. entered into Series C Purchase Agreement with accredited investors valued at approximately $22,422,000 (effective 2024-02-15).

“the Company entered into securities purchase agreements (each, a “Series C Purchase Agreement”) with accredited investors relating to an offering (the “Offering”) and the sale of an aggregate of (i) 17,307 shares of newly designated Series C Preferred Stock”

DarioHealth Corp. entered into Agreement and Plan of Merger with Twill, Inc. (effective 2024-02-15).

“(“Merger Sub”), Twill, Inc. (“Twill”) and Bilal Khan, solely in his capacity as the representatives of Twill’s stockholders and other equity holders, entered into an Agreement and Plan of”

Tomer Ben-Kiki was appointed as Chief Operating Officer at DarioHealth Corp..

“On February 15, 2024, the Company appointed Tomer Ben-Kiki, age 53, as Chief Operating Officer of the Company.”

DarioHealth Corp. shareholders approved Frequency of Advisory Vote on the Compensation of the Company's Named Executive Officers at the 2023-12-11 meeting.

“The stockholders approved three (3) years as the frequency to hold a non-binding, advisory vote relating to the compensation of the Company's named executive officers. The votes were as follows: One Year Two Years Three Years Abstain Broker Non-Votes 5,770,310 116,872 5,949,982 689,529 5,555,024”

DarioHealth Corp. shareholders approved Advisory Vote on the Compensation of the Company's Named Executive Officers at the 2023-12-11 meeting.

“The stockholders approved the compensation of the Company's named executive officers.”

DarioHealth Corp. shareholders approved Issuance of Dividend Shares to Holders of Series B-2 Convertible Preferred Stock at the 2023-12-11 meeting.

“The stockholders approved the issuance of certain dividend shares to executives and officers of the Company that hold Series B-2 Convertible Preferred Stock.”

DarioHealth Corp. shareholders approved Ratification of Auditors at the 2023-12-11 meeting.

“The stockholders ratified the appointment of Kost Forer Gabbay & Kasierer, a member of Ernst & Young Global, as the independent registered public accounting firm of the Company for the fiscal year ending December 31, 2023.”

DarioHealth Corp. shareholders approved Election of Directors at the 2023-12-11 meeting.

“The stockholders elected the following directors of the Company to hold office until the next annual meeting of stockholders and until their respective successors shall be elected and qualified or until their earlier resignation or removal.”

DarioHealth Corp. reported second quarter ended June 30, 2023 results: revenue between $6.0 million and $6.15 million.

“Dario also announced today preliminary unaudited revenue results for the three months ended June 30, 2023 of between $6.0 million and $6.15 million”

DarioHealth Corp. amended Warrant Amendment Agreement with Avenue Venture Opportunities Fund II, L.P. and Avenue Venture Opportunities Fund, L.P. (effective 2023-06-14).

“On June 14, 2023, DarioHealth Corp. (the “Company”) entered into a warrant amendment agreement (the “Warrant Amendment Agreement”) with Avenue Venture Opportunities Fund II, L.P. and Avenue Venture Opportunities Fund, L.P. (collectively, the “Holders”), relating to the warrants issued to the Holders on May 1, 2023 in conjunction with the execution of the Company’s Loan and Security Agreement.”

DarioHealth Corp.: Filed Certificate of Designation for Series B-3 Preferred Stock (effective 2023-05-05).

“On May 5, 2023, the Company filed the Series B-3 Certificate of Designation, designating 15,000 shares of Series B-3 Preferred Stock in connection with the Offering.”

DarioHealth Corp.: Filed Certificates of Designation for Series B, B-1, and B-2 Preferred Stock (effective 2023-05-01).

“On May 1, 2023, the Company filed the Series B Certificate of Designation, designating 30,000 shares of Series B Preferred Stock, the Series B-1 Certificate of Designation, designating 15,000 shares of Series B-1 Preferred Stock, and the Series B-2 Certificate of Designation, designating 15,000 shares of Series B-2 Preferred Stock in connection with the Offering.”

DarioHealth Corp. entered into Series B-3 Purchase Agreement with accredited investors (effective 2023-05-05).

“On May 5, 2023, the Company entered into purchase agreements (the “Series B-3 Purchase Agreement” and together with the Series B Purchase Agreement, the “Purchase Agreement”) with accredited investors, relating to the Offering, to an offering and the sale of an aggregate of 1,106 shares of newly designated Series B-3 Preferred Stock (the “Series B-3 Preferred Stock” and, collectively with the Series B Preferred Stock, the Series B-1 Preferred Stock and the Series B-2 Preferred Stock, the “Preferred Stock”), at a purchase price of $1,000 for each share of Preferred Stock.”

DarioHealth Corp. entered into Series B Purchase Agreement with accredited investors (effective 2023-05-01).

“On May 1, 2023, DarioHealth Corp. (the “Company”) entered into securities purchase agreements (each, a “Series B Purchase Agreement”) with accredited investors relating to an offering (the “Offering”) and the sale of an aggregate of 6,200 shares of newly designated Series B Preferred Stock (the “Series B Preferred Stock”), an aggregate of 7,946 shares of Series B-1 Preferred Stock (the “Series B-1 Preferred Stock”), and an aggregate of 150 shares of Series B-2 Preferred Stock (the “Series B-2 Preferred Stock”) at a purchase price of $1,000 for each share of Preferred Stock.”

DarioHealth Corp.: Filed certificates of designation for Series B, B-1, B-2, and B-3 Preferred Stock, specifying rights and preferences (effective 2023-05-01).

“On May 1, 2023, the Company filed the Series B Certificate of Designation, designating 30,000 shares of Series B Preferred Stock, the Series B-1 Certificate of Designation, designating 15,000 shares of Series B-1 Preferred Stock, and the Series B-2 Certificate of Designation, designating 15,000 shares of Series B-2 Preferred Stock in connection with the Offering. On May 5, 2023, the Company filed the Series B-3 Certificate of Designation, designating 15,000 shares of Series B-3 Preferred Stock in connection with the Offering.”

DarioHealth Corp. entered into Series B-3 Purchase Agreement with accredited investors (effective 2023-05-05).

“On May 5, 2023, the Company entered into purchase agreements (the "Series B-3 Purchase Agreement" and together with the Series B Purchase Agreement, the "Purchase Agreement") with accredited investors, relating to the Offering, to an offering and the sale of an aggregate of 1,106 shares of newly designated Series B-3 Preferred Stock (the "Series B-3 Preferred Stock" and, collectively with the Series B Preferred Stock, the Series B-1 Preferred Stock and the Series B-2 Preferred Stock, the "Preferred Stock"), at a purchase price of $1,000 for each share of Preferred Stock.”

DarioHealth Corp. entered into Series B Purchase Agreement with accredited investors (effective 2023-05-01).

“On May 1, 2023, DarioHealth Corp. (the "Company") entered into securities purchase agreements (each, a "Series B Purchase Agreement") with accredited investors relating to an offering (the "Offering") and the sale of an aggregate of 6,200 shares of newly designated Series B Preferred Stock (the "Series B Preferred Stock"), an aggregate of 7,946 shares of Series B-1 Preferred Stock (the "Series B-1 Preferred Stock"), and an aggregate of 150 shares of Series B-2 Preferred Stock (the "Series B-2 Preferred Stock") at a purchase price of $1,000 for each share of Preferred Stock.”

Jon Kaplan was appointed as Director at DarioHealth Corp..

“expanded the Board by one seat and appointed Jon Kaplan as a member of the Board, effective immediately.”

DarioHealth Corp. reported the fiscal year ended December 31, 2022 results: revenue approximately $27.5 million.

“DarioHealth Corp. (Nasdaq: DRIO) ("Dario" or the "Company"), a leader in the global digital therapeutics (DTx) market, today announced preliminary unaudited revenue results for the fourth quarter and full year 2022 of approximately $6.7 million and approximately $27.5 million, respectively.”

DarioHealth Corp. reported the fourth quarter ended December 31, 2022 results: revenue approximately $6.7 million.

“DarioHealth Corp. (Nasdaq: DRIO) ("Dario" or the "Company"), a leader in the global digital therapeutics (DTx) market, today announced preliminary unaudited revenue results for the fourth quarter and full year 2022 of approximately $6.7 million and approximately $27.5 million, respectively.”

DarioHealth Corp. faced acceleration on credit facility of $25 million with OrbiMed Royalty and Credit Opportunities III, LP maturing June 9, 2027.

“the Company started repayment of the outstanding principal amount of the initial tranche of $25 million issued as part of the Loan Facility, together with a repayment premium and other fees in monthly installments of up to $518,500 beginning as of January 31, 2023, and continuing through the maturity date, or June 9, 2027.”

Dror Bacher was terminated as Chief Operating Officer at DarioHealth Corp..

“On January 23, 2023, DarioHealth Corp. (the “Company”), through its wholly owned subsidiary Labstyle Innovation Ltd., executed a Termination of Employment and Separation Agreement (the “Agreement”) with Dror Bacher, the Company’s Chief Operating Officer, pursuant to which Mr. Bacher’s position as Chief Operating Officer was terminated with immediate effect.”

DarioHealth Corp. shareholders approved Ratification of Auditors at the 2022-12-31 meeting.

“The stockholders ratified the appointment of Kost Forer Gabbay & Kasierer, a member of Ernst & Young Global, as the independent registered public accounting firm of the Company for the fiscal year ending December 31, 2022. The votes were as follows (including shares of preferred stock eligible to vote, on an as converted basis): For Against Abstain 15,380,546 1,919,212 4,160”

DarioHealth Corp. shareholders approved Incentive Plan Proposal.

“The stockholders approved the Plan Amendment. The Plan Amendment proposal required the affirmative vote of a majority of the votes cast at the 2022 Annual Meeting. The votes were as follows (including shares of preferred stock eligible to vote, on an as converted basis): For Against Abstain Broker Non-Votes 9,340,879 3,672,599 57,104 4,233,336”

DarioHealth Corp. shareholders approved Election of Directors.

“The stockholders elected the following directors of the Company to hold office until the next annual meeting of stockholders and until their respective successors shall be elected and qualified or until their earlier resignation or removal. The votes were as follows (including shares of preferred stock eligible to vote, on an as converted basis): Director Name For Against Abstain Broker Non-Votes Hila Karah 11,309,066 1,716,541 44,975 4,233,336 Dennis Matheis 11,319,813 1,710,588 40,181 4,233,336 Dennis M. McGrath 9,803,299 3,222,302 44,981 4,233,336 Erez Raphael 12,826,044 232,018 12,520 4,233,336 Yoav Shaked 11,310,152 1,741,869 18,561 4,233,336 Adam K. Stern 12,986,045 57,691 26,846 4,233,336”

Prof. Richard Stone departed as Director at DarioHealth Corp..

“On May 30, 2022, DarioHealth Corp. (the “Company”) was informed of the death of Prof. Richard Stone, a member of the Company’s Board of Directors (the “Board”).”

Oded Cohen changed role as Senior Vice President of Strategy M&A and MSK at DarioHealth Corp..

“On November 25, 2021, Mr. Oded Cohen was relieved from his role as General Manager of MSK and he was reassigned to serve as Senior Vice President of Strategy M&A and MSK of DarioHealth Corp.”